Latest Plasmodium vivax Stories
An international team of scientists has traced the origin of Plasmodium vivax, the second-worst malaria parasite of humans, to Africa
Researchers have identified a potential new weapon and approach for attacking the parasites that cause malaria.
Malaria is one of the major infectious diseases transmitted by mosquitos, with enormous impact on quality of life.
Human migrations—from the prehistoric epoch to the present day—have extended cultures across the globe.
After sequencing the genome of several malaria-related parasites, scientists found that the protozoans responsible for the deadly disease are very genetically diverse and therefore difficult to eradicate, according to their report publish this week in Nature Genetics.
Malaria infections among infants can be cut by up to 30 per cent when antimalarial drugs are given intermittently over a 12 month period, a three-year clinical trial in Papua New Guinea has shown.
The largest ever study to assess the effects of malaria and its treatment in the first trimester of pregnancy has shown that the disease significantly increases the risk of miscarriage, but that treating with antimalarial drugs is relatively safe and reduces this risk.
A mutation on the surface of human red blood cells provides protection against malaria caused by the parasite Plasmodium vivax.
Malaria is a major global health concern, and researchers are in need of new therapeutic approaches.
ROCKVILLE, Md., June 29, 2011 /PRNewswire-USNewswire/ -- Sanaria's mission is to develop and commercialize whole-parasite malaria vaccines that confer high-level, long-lasting protection against malaria caused by Plasmodium falciparum and P. vivax.